Contributions of PET and SPECT to the understanding of the pathophysiology of Parkinson’s disease
Identifieur interne : 000208 ( France/Analysis ); précédent : 000207; suivant : 000209Contributions of PET and SPECT to the understanding of the pathophysiology of Parkinson’s disease
Auteurs : S. Thobois [France] ; S. Guillouet [France] ; E. Broussolle [France]Source :
- Neurophysiologie Clinique / Clinical Neurophysiology [ 0987-7053 ] ; 2001.
English descriptors
- KwdEn :
- Parkinson’s disease, activation, caudate nucleus, cerebral blood flow (rCBF), cerebral metabolism, dopamine, parkinsonism, positron emission tomography (PET), putamen, regional, single photon emission computed tomography (SPECT), striatum, 〚11C〛-Raclopride, 〚123I〛-FP-β-CIT, 〚123〛-β-CIT, 〚15O〛-H2O, 〚18F〛-desoxyglucose, 〚18F〛-fluoro-L-Dopa.
Abstract
Positron emission tomography (PET) and single photon emission computed tomography (SPECT) provide the means to studying in vivo the neurochemical, hemodynamic or metabolic consequences of the degeneration of the nigrostriatal dopaminergic system in Parkinson’s disease (PD). The extent of striatal dopaminergic denervation can be quantified with radiotracers as 〚18F〛FDopa for PET and 〚123I〛tropanes for SPECT. There are other radiotracers such as 〚11C〛Dopa and meta-tyrosines as well as PET tracers for uptake sites. Striatal uptake of 〚18F〛FDopa and 〚123I〛tropanes is markedly decreased in PD, more in the putamen than in the caudate nucleus, and inversely correlates with the severity of motor signs and with duration of disease. PET and SPECT make possible the assessment by noninvasive means of the changes in dopamine receptor density, the effect of neuronal transplants or neuroprotective treatments in PD patients, or the nigrostriatal dopaminergic function in at-risk subjects. Activation studies using cerebral blood flow and metabolism measurements during a motor task reveal an impaired ability to activate the supplementary motor area and dorsolateral prefrontal cortex in PD. This functional disability is reversed by the use of dopaminergic medication or by surgical treatment by pallidotomy or deep brain stimulation. The differential diagnosis between PD and multiple system atrophy, progressive supranuclear palsy or corticobasal degeneration is not yet clearly established by PET and SPECT, even though these syndromes have some particular neurochemical and metabolic profiles. On the other hand, PET and SPECT are useful for distinguishing PD from Dopa-responsive dystonia, or for assessing the integrity of the nigrostriatal dopaminergic pathway in atypical cases of postural tremor or iatrogenic parkinsonian syndromes.
Url:
DOI: 10.1016/S0987-7053(01)00273-8
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Main, to step Corpus: 000B12
- to stream Main, to step Curation: 000972
- to stream Main, to step Exploration: 001A89
- to stream France, to step Extraction: 000208
Links to Exploration step
ISTEX:48BB202AA40A68D291F782603E3E5A82BFD85AABLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Contributions of PET and SPECT to the understanding of the pathophysiology of Parkinson’s disease</title><author><name sortKey="Thobois, S" sort="Thobois, S" uniqKey="Thobois S" first="S" last="Thobois">S. Thobois</name></author><author><name sortKey="Guillouet, S" sort="Guillouet, S" uniqKey="Guillouet S" first="S" last="Guillouet">S. Guillouet</name></author><author><name sortKey="Broussolle, E" sort="Broussolle, E" uniqKey="Broussolle E" first="E" last="Broussolle">E. Broussolle</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:48BB202AA40A68D291F782603E3E5A82BFD85AAB</idno><date when="2001" year="2001">2001</date><idno type="doi">10.1016/S0987-7053(01)00273-8</idno><idno type="url">https://api.istex.fr/document/48BB202AA40A68D291F782603E3E5A82BFD85AAB/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000B12</idno><idno type="wicri:Area/Main/Curation">000972</idno><idno type="wicri:Area/Main/Exploration">001A89</idno><idno type="wicri:Area/France/Extraction">000208</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Contributions of PET and SPECT to the understanding of the pathophysiology of Parkinson’s disease</title><author><name sortKey="Thobois, S" sort="Thobois, S" uniqKey="Thobois S" first="S" last="Thobois">S. Thobois</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>CERMEP et service de neurologie D, hôpital neurologique Pierre-Wertheimer, 59, boulevard Pinel, Lyon</wicri:regionArea><placeName><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Guillouet, S" sort="Guillouet, S" uniqKey="Guillouet S" first="S" last="Guillouet">S. Guillouet</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>CERMEP et service de neurologie D, hôpital neurologique Pierre-Wertheimer, 59, boulevard Pinel, Lyon</wicri:regionArea><placeName><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Broussolle, E" sort="Broussolle, E" uniqKey="Broussolle E" first="E" last="Broussolle">E. Broussolle</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>CERMEP et service de neurologie D, hôpital neurologique Pierre-Wertheimer, 59, boulevard Pinel, Lyon</wicri:regionArea><placeName><settlement type="city">Lyon</settlement></placeName></affiliation><affiliation wicri:level="1"><country wicri:rule="url">France</country></affiliation></author></analytic><monogr></monogr><series><title level="j">Neurophysiologie Clinique / Clinical Neurophysiology</title><title level="j" type="abbrev">NEUCLI</title><idno type="ISSN">0987-7053</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="2001">2001</date><biblScope unit="volume">31</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="321">321</biblScope><biblScope unit="page" to="340">340</biblScope></imprint><idno type="ISSN">0987-7053</idno></series><idno type="istex">48BB202AA40A68D291F782603E3E5A82BFD85AAB</idno><idno type="DOI">10.1016/S0987-7053(01)00273-8</idno><idno type="PII">S0987-7053(01)00273-8</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0987-7053</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson’s disease</term><term>activation</term><term>caudate nucleus</term><term>cerebral blood flow (rCBF)</term><term>cerebral metabolism</term><term>dopamine</term><term>parkinsonism</term><term>positron emission tomography (PET)</term><term>putamen</term><term>regional</term><term>single photon emission computed tomography (SPECT)</term><term>striatum</term><term>〚11C〛-Raclopride</term><term>〚123I〛-FP-β-CIT</term><term>〚123〛-β-CIT</term><term>〚15O〛-H2O</term><term>〚18F〛-desoxyglucose</term><term>〚18F〛-fluoro-L-Dopa</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Positron emission tomography (PET) and single photon emission computed tomography (SPECT) provide the means to studying in vivo the neurochemical, hemodynamic or metabolic consequences of the degeneration of the nigrostriatal dopaminergic system in Parkinson’s disease (PD). The extent of striatal dopaminergic denervation can be quantified with radiotracers as 〚18F〛FDopa for PET and 〚123I〛tropanes for SPECT. There are other radiotracers such as 〚11C〛Dopa and meta-tyrosines as well as PET tracers for uptake sites. Striatal uptake of 〚18F〛FDopa and 〚123I〛tropanes is markedly decreased in PD, more in the putamen than in the caudate nucleus, and inversely correlates with the severity of motor signs and with duration of disease. PET and SPECT make possible the assessment by noninvasive means of the changes in dopamine receptor density, the effect of neuronal transplants or neuroprotective treatments in PD patients, or the nigrostriatal dopaminergic function in at-risk subjects. Activation studies using cerebral blood flow and metabolism measurements during a motor task reveal an impaired ability to activate the supplementary motor area and dorsolateral prefrontal cortex in PD. This functional disability is reversed by the use of dopaminergic medication or by surgical treatment by pallidotomy or deep brain stimulation. The differential diagnosis between PD and multiple system atrophy, progressive supranuclear palsy or corticobasal degeneration is not yet clearly established by PET and SPECT, even though these syndromes have some particular neurochemical and metabolic profiles. On the other hand, PET and SPECT are useful for distinguishing PD from Dopa-responsive dystonia, or for assessing the integrity of the nigrostriatal dopaminergic pathway in atypical cases of postural tremor or iatrogenic parkinsonian syndromes.</div></front></TEI><affiliations><list><country><li>France</li></country><settlement><li>Lyon</li></settlement></list><tree><country name="France"><noRegion><name sortKey="Thobois, S" sort="Thobois, S" uniqKey="Thobois S" first="S" last="Thobois">S. Thobois</name></noRegion><name sortKey="Broussolle, E" sort="Broussolle, E" uniqKey="Broussolle E" first="E" last="Broussolle">E. Broussolle</name><name sortKey="Broussolle, E" sort="Broussolle, E" uniqKey="Broussolle E" first="E" last="Broussolle">E. Broussolle</name><name sortKey="Guillouet, S" sort="Guillouet, S" uniqKey="Guillouet S" first="S" last="Guillouet">S. Guillouet</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/France/Analysis
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000208 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/France/Analysis/biblio.hfd -nk 000208 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= France
|étape= Analysis
|type= RBID
|clé= ISTEX:48BB202AA40A68D291F782603E3E5A82BFD85AAB
|texte= Contributions of PET and SPECT to the understanding of the pathophysiology of Parkinson’s disease
}}
| This area was generated with Dilib version V0.6.23. |  |